Afatinib as first-line treatment for patients with advanced non-small-cell lung cancer harboring EGFR mutations: focus on LUX-Lung 3 and LUX-Lung 6 phase III trials.
作者信息
Passaro Antonio, Gori Bruno, de Marinis Filippo
机构信息
1 Oncological Pulmonary Unit, San Camillo, High Specialization Hospital, Rome, Italy.
出版信息
J Thorac Dis. 2013 Aug;5(4):383-4. doi: 10.3978/j.issn.2072-1439.2013.07.32.
Abstract
摘要
相似文献
1
Afatinib as first-line treatment for patients with advanced non-small-cell lung cancer harboring EGFR mutations: focus on LUX-Lung 3 and LUX-Lung 6 phase III trials.阿法替尼作为一线治疗用于携带表皮生长因子受体（EGFR）突变的晚期非小细胞肺癌患者：聚焦LUX-Lung 3和LUX-Lung 6 III期试验
J Thorac Dis. 2013 Aug;5(4):383-4. doi: 10.3978/j.issn.2072-1439.2013.07.32.
2
Afatinib for the first-line treatment of patients with metastatic EGFR-positive NSCLC: a look at the data.阿法替尼用于转移性表皮生长因子受体（EGFR）阳性非小细胞肺癌（NSCLC）患者的一线治疗：数据解读
Expert Rev Clin Pharmacol. 2016 Oct;9(10):1283-1288. doi: 10.1080/17512433.2016.1233059. Epub 2016 Sep 20.
3
Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6).表皮生长因子受体（EGFR）突变类型是否影响晚期 EGFR 突变阳性非小细胞肺癌患者的患者报告结局？阿法替尼与化疗（LUX-Lung 3 和 LUX-Lung 6）比较的两项大型 III 期研究的分析。
Patient. 2018 Feb;11(1):131-141. doi: 10.1007/s40271-017-0287-z.
4
Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.阿法替尼用于经可逆性表皮生长因子受体（EGFR）抑制剂治疗的伴有罕见EGFR突变的非小细胞肺癌
Oncologist. 2015 Oct;20(10):1167-74. doi: 10.1634/theoncologist.2015-0073. Epub 2015 Sep 9.
5
[Afatinib as first-line therapy in mutation-positive EGFR. Results by type of mutation].[阿法替尼作为EGFR突变阳性患者的一线治疗。按突变类型划分的结果]
Med Clin (Barc). 2016 Apr;146 Suppl 1:12-8. doi: 10.1016/S0025-7753(16)30258-5.
6
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.阿法替尼治疗携带非典型 EGFR 突变的晚期非小细胞肺癌患者的临床活性：LUX-Lung 2、LUX-Lung 3 和 LUX-Lung 6 的联合事后分析。
Lancet Oncol. 2015 Jul;16(7):830-8. doi: 10.1016/S1470-2045(15)00026-1. Epub 2015 Jun 4.
7
First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials.一线阿法替尼治疗晚期 EGFRm+ NSCLC：LUX-Lung 3、6、7 试验中长程应答者的分析。
Lung Cancer. 2019 Jul;133:10-19. doi: 10.1016/j.lungcan.2019.04.006. Epub 2019 Apr 8.
8
[Efficacy of first-line afatinib versus chemotherapy in EGFR mutation positive pulmonary adenocarcinoma].一线阿法替尼与化疗治疗表皮生长因子受体（EGFR）突变阳性肺腺癌的疗效
Magy Onkol. 2014 Dec;58(4):325-9. Epub 2014 Oct 17.
9
Afatinib: A Review in Advanced Non-Small Cell Lung Cancer.阿法替尼：治疗晚期非小细胞肺癌的研究进展。
Target Oncol. 2016 Dec;11(6):825-835. doi: 10.1007/s11523-016-0465-2.
10
Afatinib for the treatment of mutation-positive NSCLC: A review of clinical findings.阿法替尼用于治疗突变阳性非小细胞肺癌：临床研究结果综述
J Oncol Pharm Pract. 2020 Sep;26(6):1461-1474. doi: 10.1177/1078155220931926. Epub 2020 Jun 20.
引用本文的文献
1
The Association of Annexin A1 and Chemosensitivity to Osimertinib in Lung Cancer Cells.肺癌细胞中膜联蛋白A1与对奥希替尼化疗敏感性的关联。
Cancers (Basel). 2021 Aug 15;13(16):4106. doi: 10.3390/cancers13164106.
2
Long-lasting response to afatinib that persisted after treatment discontinuation in a case of -mutated lung adenocarcinoma.一例KRAS基因突变型肺腺癌患者在停用阿法替尼治疗后仍持续存在的长期反应。 （注：原文中“-mutated”推测应为“KRAS-mutated”，已补充完整进行翻译）
BMJ Case Rep. 2019 Jan 31;12(1):e227383. doi: 10.1136/bcr-2018-227383.
3
[Current Status and Progress in Molecular Imaging of Non-small Cell Lung
Cancer for Molecular Targeted EGFR-TKI Treatment Sensitivity and
Treatment Tolerance Prediction].[非小细胞肺癌分子成像在分子靶向EGFR-TKI治疗敏感性及治疗耐受性预测中的现状与进展]
Zhongguo Fei Ai Za Zhi. 2017 Dec 20;20(12):852-856. doi: 10.3779/j.issn.1009-3419.2017.12.10.
4
Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors and Non-Small Cell Lung Cancer (NSCLC) - Advances in Molecular Diagnostic Techniques to Facilitate Targeted Therapy.表皮生长因子受体（EGFR）激酶抑制剂与非小细胞肺癌（NSCLC）——促进靶向治疗的分子诊断技术进展
Pathol Oncol Res. 2018 Oct;24(4):723-731. doi: 10.1007/s12253-017-0377-1. Epub 2017 Dec 21.
5
Cytotoxicity of allitinib, an irreversible anti-EGFR agent, in a large panel of human cancer-derived cell lines: KRAS mutation status as a predictive biomarker.阿昔替尼，一种不可逆的抗 EGFR 药物，在一大类人类肿瘤细胞系中的细胞毒性：KRAS 基因突变状态作为预测生物标志物。
Cell Oncol (Dordr). 2016 Jun;39(3):253-63. doi: 10.1007/s13402-016-0270-z. Epub 2016 Feb 26.
6
Prolonged survival with erlotinib followed by afatinib in a caucasian smoker with metastatic, poorly differentiated large cell carcinoma of the lung: a case report.一名患有转移性低分化肺大细胞癌的白人吸烟者先后使用厄洛替尼和阿法替尼后长期存活：病例报告
Cancer Biol Ther. 2015;16(10):1434-7. doi: 10.1080/15384047.2015.1070993. Epub 2015 Jul 17.
7
Lentiviral vector-mediated RBM5 overexpression downregulates EGFR expression in human non-small cell lung cancer cells.慢病毒载体介导的RBM5过表达下调人非小细胞肺癌细胞中的表皮生长因子受体（EGFR）表达。
World J Surg Oncol. 2014 Dec 2;12:367. doi: 10.1186/1477-7819-12-367.
本文引用的文献
1
Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations.LUX-Lung 3 研究：阿法替尼或顺铂/培美曲塞治疗伴有 EGFR 突变的晚期肺腺癌患者的 III 期研究：症状控制和生活质量。
J Clin Oncol. 2013 Sep 20;31(27):3342-50. doi: 10.1200/JCO.2012.46.1764. Epub 2013 Jul 1.
2
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.III 期研究阿法替尼或顺铂加培美曲塞治疗 EGFR 突变的转移性肺腺癌患者。
J Clin Oncol. 2013 Sep 20;31(27):3327-34. doi: 10.1200/JCO.2012.44.2806. Epub 2013 Jul 1.
3
First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.First-SIGNAL：一线单药易瑞沙对比吉西他滨和顺铂治疗从不吸烟肺腺癌的临床试验。
J Clin Oncol. 2012 Apr 1;30(10):1122-8. doi: 10.1200/JCO.2011.36.8456. Epub 2012 Feb 27.
4
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.厄洛替尼对比标准化疗用于治疗欧洲晚期 EGFR 突变阳性非小细胞肺癌患者的一线治疗（EURTAC）：一项多中心、开放标签、随机、3 期临床试验。
Lancet Oncol. 2012 Mar;13(3):239-46. doi: 10.1016/S1470-2045(11)70393-X. Epub 2012 Jan 26.
5
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.厄洛替尼对比化疗用于治疗晚期 EGFR 突变阳性非小细胞肺癌患者的一线治疗（OPTIMAL、CTONG-0802）：一项多中心、开放标签、随机、III 期研究。
Lancet Oncol. 2011 Aug;12(8):735-42. doi: 10.1016/S1470-2045(11)70184-X. Epub 2011 Jul 23.
6
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.吉非替尼对比顺铂联合多西他赛用于治疗表皮生长因子受体突变的非小细胞肺癌患者（WJTOG3405）：一项开放标签、随机对照 3 期临床试验。
Lancet Oncol. 2010 Feb;11(2):121-8. doi: 10.1016/S1470-2045(09)70364-X. Epub 2009 Dec 18.
7
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.吉非替尼或卡铂-紫杉醇用于治疗肺腺癌。
N Engl J Med. 2009 Sep 3;361(10):947-57. doi: 10.1056/NEJMoa0810699. Epub 2009 Aug 19.
Zotero 插件